Assignee
GLENMARK SPECIALTY SA
CH·21 granted patents·9 pending applications·34 citations·filing 2016–2025
Top patents by PatentIndex Score
30 records- 0191US12303635B2Dispensing device and pharmaceutical composition for the treatment of rhinitisGLENMARK SPECIALTY SA·Filed 2023·Granted May 20, 2025·1 cites·10 claims
- 0291US9750754B2Stable fixed dose pharmaceutical composition comprising mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2016·Granted Sep 5, 2017·6 cites·51 claims
- 0390US9987260B2Tiotropium inhalation solution for nebulizationGLENMARK SPECIALTY SA·Filed 2017·Granted Jun 5, 2018·5 cites·39 claims
- 0489US9757365B2Tiotropium inhalation solution for nebulizationGLENMARK SPECIALTY SA·Filed 2016·Granted Sep 12, 2017·6 cites·35 claims
- 0582US10016443B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2017·Granted Jul 10, 2018·2 cites·24 claims
- 0681US2024156840A1Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2023·Application pending·0 cites
- 0779US9937189B2Stable fixed dose pharmaceutical composition comprising mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2016·Granted Apr 10, 2018·1 cites·36 claims
- 0878US12064442B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2022·Granted Aug 20, 2024·0 cites·18 claims
- 0970US11400101B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2020·Granted Aug 2, 2022·0 cites·26 claims
- 1070US10632109B2Tiotropium inhalation solution for nebulizationGLENMARK SPECIALTY SA·Filed 2019·Granted Apr 28, 2020·0 cites·58 claims
- 1168US10765686B2Stable fixed dose pharmaceutical composition comprising mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2017·Granted Sep 8, 2020·0 cites·14 claims
- 1268US10561672B2Stable fixed dose pharmaceutical composition comprising mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2017·Granted Feb 18, 2020·0 cites·22 claims
- 1368US10517880B2Stable fixed dose pharmaceutical composition comprising mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2017·Granted Dec 31, 2019·0 cites·33 claims
- 1468US10376526B2Stable fixed dose pharmaceutical composition comprising mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2017·Granted Aug 13, 2019·0 cites·32 claims
- 1567US11679210B2Dispensing device and pharmaceutical composition for the treatment of rhinitisGLENMARK SPECIALTY SA·Filed 2018·Granted Jun 20, 2023·1 cites·16 claims
- 1667US10632108B2Tiotropium inhalation solution for nebulizationGLENMARK SPECIALTY SA·Filed 2018·Granted Apr 28, 2020·0 cites·20 claims
- 1767USD863529SInhalerGLENMARK SPECIALTY SA·Filed 2016·Granted Oct 15, 2019·12 cites·1 claims
- 1866US2025161328A1Nasal spray compositionGLENMARK SPECIALTY SA·Filed 2024·Application pending·0 cites
- 1964US2025242115A1Dispensing device and pharmaceutical composition for the treatment of rhinitisGLENMARK SPECIALTY SA·Filed 2025·Application pending·0 cites
- 2058US10758550B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2018·Granted Sep 1, 2020·0 cites·32 claims
- 2155US12558314B1Pressurized inhalation composition of tiotropiumGLENMARK SPECIALTY SA·Filed 2024·Granted Feb 24, 2026·0 cites·30 claims
- 2255US10653683B2Tiotropium inhalation solution for nebulizationGLENMARK SPECIALTY SA·Filed 2019·Granted May 19, 2020·0 cites·71 claims
- 2352US2020163955A1Sterile compositions of indacaterol suitable for nebulizationGLENMARK SPECIALTY SA·Filed 2019·Application pending·0 cites
- 2450US10653661B2Treatment of allergic rhinitis using a combination of mometasone and olopatadineGLENMARK SPECIALTY SA·Filed 2017·Granted May 19, 2020·0 cites·5 claims
- 2548US10555903B2Nebulizable compositions of tiotropium and formoterolGLENMARK SPECIALTY SA·Filed 2017·Granted Feb 11, 2020·0 cites·30 claims
- 2648US2023312486A1Polymorphic forms of a ror inhibiting compound and processes for its preparationGLENMARK SPECIALTY SA·Filed 2021·Application pending·0 cites
- 2746US2020215051A1Nebulization composition comprising tiotropium and indacaterolGLENMARK SPECIALTY SA·Filed 2020·Application pending·0 cites
- 2842US2024108617A1An inhalable dry powder composition for pulmonary diseasesGLENMARK SPECIALTY SA·Filed 2020·Application pending·0 cites
- 2938US2018133151A1Nebulized tiotropiumGLENMARK SPECIALTY SA·Filed 2017·Application pending·0 cites
- 3035US2016310410A1Pharmaceutical compositions comprising arformoterol and glycopyrroniumGLENMARK SPECIALTY SA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when GLENMARK SPECIALTY SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →